Updated AAN/AHS guideline broadens approach to migraine prevention in adults
12 Oct 2026
Fourteen years after the last evidence-based recommendations from the American Academy of Neurology and the American Headache Society (AAN/AHS) on migraine prevention, new guidance now reflects a significantly broader treatment landscape. It incorporates established therapies alongside newer migraine-specific approaches, including oral calcitonin gene-related peptide (CGRP) receptor antagonists such as atogepant, and extends its scope to both episodic and chronic migraine*. [Neurology 2026;107(7):e214881]
Developed from a systematic review of 217 randomised controlled trials, the new guideline incorporates established preventive therapies alongside newer migraine-specific treatments, including CGRP-targeting therapies. Importantly, it also provides practical recommendations on when to initiate prevention, treatment selection, management of special populations and comorbidities, treatment monitoring, and discontinuation. [Neurology 2026;107(7):e214881; Neurology 2026;107(7):e218112]
Resources
